Print
Email
Print Edition Stories
Hopkinton’s Caliper Life Sciences Inc. will be acquired by Waltham life sciences instrumentation giant PerkinElmer Inc. for approximately $600 million in cash, according to a release.
PerkinElmer (NYSE: PKI) reports it has signed a definitive agreement to buy Caliper (Nasdaq: CALP) for $10.50 per share, Kevin Hrusovsky, CEO of Caliper Life Sciences is expected to join the PerkinElmer senior leadership team once the sale close, but the release did not state in what capacity. Robert F. Friel, chairman and CEO of PerkinElmer, cited Caliper’s “proven leadership” and the talent of the Caliper team in a statement.
At $10.50 per share, stockholders will receive a 42 percent premium over the closing price of $7.39 per share as of Wednesday, PerkinElmer officials said. The sale has already won unanimous support of the boards of directors of both companies, and should close in the fourth quarter of 2011.
One month ago, Caliper settled two patent infringement lawsuits with Rochester, N.Y.-based Carestream Health Inc. The first lawsuit was filed in February 2010 by Caliper and its wholly owned subsidiary Xenogen, as well as Stanford University. That suit alleged that Carestream infringed on seven imaging patents that Stanford licensed exclusively to Xenogen through its instrument systems marketing and sales. The second suit by Carestream, filed in July 2010, alleged that IVIS Lumina XR System from Caliper infringed on a multimodal in-vivo imaging patent from Carestream.
Caliper reported in July that its LabChip Dx, a microfluidic-based diagnostic chip, received CE Mark registration in Europe.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
